FDA Warning Letter Blasts Mylan’s Lax API Impurity Controls
Cites Equipment Cleaning And Monitoring Of Recovered Solvents For Impurities
Executive Summary
Concerned about another possible nitrosamine scare, the US FDA has sent a warning letter to Mylan focusing on the firm’s failure to control contamination risks of its APIs and inadequate testing of reused solvents.